BETA
Beta Drugs Limited
Oncology branded generics, CDMO, dermatology and IVF products
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
betadrugslimited.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Beta Drugs makes cancer medicines sold in India under the Adley brand, and also does contract manufacturing for other drug companies, exports formulations and supplies active pharmaceutical ingredients (APIs).
Company snapshot
79thBy market cap
Ranked among 119 companies in Pharmaceuticals.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 87 Cr | 94 Cr | 126 Cr |
| Operating expenses (approx.) | 70 Cr | 76 Cr | 98 Cr |
| EBITDA | 17 Cr | 18 Cr | 27 Cr |
| OPM % | 19.5% | 18.8% | 21.8% |
| Other income | 2 Cr | 3 Cr | 2 Cr |
| Interest | 4 Cr | 4 Cr | 3 Cr |
| Depreciation | 4 Cr | 5 Cr | 4 Cr |
| Profit before tax | 10 Cr | 12 Cr | 22 Cr |
| Tax % | 18.7% | 23.5% | 25.2% |
| Net profit | 9 Cr | 9 Cr | 16 Cr |
| EPS (₹) | ₹8.40 | ₹8.93 | ₹14.78 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 362 Cr | 385 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 292 Cr | 309 Cr | Sign in free for the trailing twelve months |
| EBITDA | 70 Cr | 76 Cr | Sign in free for the trailing twelve months |
| OPM % | 19.3% | 19.7% | Sign in free for the trailing twelve months |
| Other income | 6 Cr | 11 Cr | Sign in free for the trailing twelve months |
| Interest | 7 Cr | 15 Cr | Sign in free for the trailing twelve months |
| Depreciation | 13 Cr | 17 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 57 Cr | 54 Cr | Sign in free for the trailing twelve months |
| Tax % | 25.5% | 23.7% | Sign in free for the trailing twelve months |
| Net profit | 42 Cr | 41 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹42.02 | ₹40.92 | Sign in free for the trailing twelve months |
| Dividend payout % | 0.0% | 0.0% | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 10 Cr | 10 Cr |
| Reserves | 187 Cr | 235 Cr |
| Borrowings | — | 148 Cr |
| Other liabilities | 239 Cr | 103 Cr |
| Total liabilities | 436 Cr | 496 Cr |
| Fixed assets (net) | 80 Cr | 115 Cr |
| CWIP | — | 0 Cr |
| Investments | 0 Cr | 0 Cr |
| Inventories | 60 Cr | 74 Cr |
| Trade receivables | 103 Cr | 119 Cr |
| Cash & bank | 0.22 Cr | 125 Cr |
| Other assets | 193 Cr | 62 Cr |
| Total assets | 436 Cr | 496 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Cash from operating activity | 32 Cr | 37 Cr |
| Cash from investing | -36 Cr | -51 Cr |
| Cash from financing | 118 Cr | -8 Cr |
| Net cash flow | 114 Cr | -22 Cr |
| Free cash flow (OCF − Capex) | -5 Cr | -16 Cr |
Ratios
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| ROCE % | 32.5% | 17.8% |
| ROE % | 21.5% | 16.9% |
| Debtor days | 103 | 113 |
| Inventory days | 124 | 156 |
| Days payable | 148 | 169 |
| Cash conversion cycle | 79 | 100 |
| OCF / EBITDA % | 45.1% | 49.3% |
| Debt / equity | 0.0071 | 0.60 |
| Current ratio | 3.22 | 3.10 |
| Net debt / EBITDA | -0.0031 | 0.30 |